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Introduction
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and also occurs in children. Despite the genetic heterogeneity of the disease, patients have been treated for decades with similar combinations of cytarabine and anthracyclines with little improvement in overall survival 1 . Although the majority of patients (50-60%) under 60 years achieve complete remission with traditional anthracycline-and cytarabine-based induction regimens, the long-term survival rates continue to be around 30% to 40% for adults and 60% for children [2] [3] [4] [5] [6] . Outcomes are worse for patients ≥ 60 years, with complete response rates in the range of 40 to 55% and poor long-term survival rates 7 . The main reason for treatment failure among patients with AML is resistance to therapy [8] [9] [10] . In addition, treatment with cytarabine is associated with a number of adverse side effects including myelosuppression, infections, mucositis, neurotoxicity and acute pulmonary syndrome 11 .
Cytarabine requires activation through intracellular phosphorylation to araCtriphosphate (ara-CTP). The mechanism of action of cytarabine involves incorporation of ara-CTP in place of deoxycytidine triphosphate (dCTP) resulting in chain termination, blocking DNA and RNA synthesis and causing leukemic cell death 12, 13 . One of the greatest predictors of response to cytarabine is the intracellular concentration of ara-CTP ex vivo and in circulating blasts of patients 14, 15 . Resistance is likely due to inefficient uptake of araCTP, reduced levels of deoxycytidine kinase (DCK), increased levels of deactivating enzymes 5'-nucleotidase (NT5C2) or cytidine deaminase (CDA), or increased cellular dCTP pools that compete with ara-CTP for incorporation in DNA.
For personal use only. on November 1, 2017 . by guest www.bloodjournal.org From Candidate approaches and genome-wide association studies (GWAS) have been used to identify genetic variables that are important in inter-individual variability in sensitivity to cytarabine. Candidate gene studies revealed that genes within the cytarabine pharmacokinetic pathway including DCK, CDA, NT5C2, NT5C3 and human equilibrative nucleoside transporter 1 (hENT1) contribute to sensitivity to cytarabine 16 .
In previous work 17, 18 , we found genetic variants associated with cytarabine sensitivity in 85 European (CEU) and 89 African (YRI) LCLs that were specific to each population (505 SNPs for CEU and 397 SNPs for YRI at p < 1 x 10 -4 , no overlap) as well as associated variants in the "African American from the Southwestern United States"
(ASW) population. The results of these cell-based models can be used in conjunction with clinical trials for discovery of SNPs associated with chemotherapeutic sensitivity,
given the challenge of accruing large patient cohorts receiving the same drug regimen for discovery and replication GWAS in oncology. In this study, our goal was to identify variants that associate with cytarabine-induced cytotoxicity in 523 LCLs from different world populations representing European, African, Asian, and African American ancestries providing a robust set of SNPs for studies in clinical trials. We evaluated the significance of the most highly ranked SNPs (p < 10 -5 ) with cytarabine-induced apoptosis and with treatment outcome in AML patients who received cytarabine-containing therapy.
Material and Methods

Meta-analysis of Six GWA Studies
Details on the cytotoxicity assays in LCLs and the GWAS in individual panels are found in the Supplementary Materials. To determine SNP associations with cytarabineFor personal use only. on November 1, 2017. by guest www.bloodjournal.org From induced cytotoxicity across populations, we conducted a meta-analysis on the results of the individual GWAS from the 6 panels using METAL, which combines SNP p-values across studies taking into account a study-specific weight (sample size) and direction of effect (positive or negative beta) 19 . Z-scores, derived from the p-values for each SNP,
were combined across studies in a weighted sum, wherein the weights were defined to be proportional to the square-root of the sample size for each study 19 . The Q-Q plot of the corresponding p-values was generated using R. Local region plots of top associated SNPs were generated by LocusZoom 20 .
Association of Top Meta-analysis SNPs with Apoptosis
Apoptosis may underlie cytarabine-induced cytotoxicity; thus, the top thirty seven SNPs (p < 1 x 10 -5 ) selected from the meta-analysis of cytotoxicity in LCLs were tested for association with cytarabine-induced apoptosis. The apoptotic effects of cytarabine were determined in CEU1/2, YRI1/2, ASW and Han Chinese in Beijing, China (CHB)
samples. Apoptosis, as measured by caspase 3/7 activation induced by 40 µM cytarabine 24 hours post drug treatment, was measured as previously described 21 . Association analyses with apoptosis were done within each panel; results were then combined into a single p-value for each SNP using the meta-analysis method.
Clinical Samples
Details of the multicenter AML02 study trial (NCT00136084) protocol and MTT cytotoxicity assay as described previously 22, 23 . The statistical analysis of clinical samples is described in Supplemental Materials.
Evaluation of Meta-analysis LCL SNPs in Patients
We tested the 33 SNPs that had an association with cytarabine-induced cytotoxicity in LCLs (p<1 x 10 -5 ) for association (p<0.05 and concordant direction) with either cytarabine IC 50 in leukemia cells or with clinical response parameters (MRD on day 22, OS, or TRM). We refer to these SNPs as "clinically validated SNPs".
For assessment of the statistical significance of the number of clinically validated SNPs, patient label was permuted (n=5000) in the Caucasian patients while preserving the genotype correlation structure among the 33 SNPs and the correlation structure among the clinical traits tested. In each permuted dataset, the association tests with the clinical phenotypes were performed; SNPs with p<0.05 were selected. A permuted dataset was considered a "success" if the number of (unique) selected SNPs from the association tests was equal to or greater than the number of clinically validated SNPs.
Empirical significance of the excess of clinically validated SNPs was estimated as the proportion of such "successes".
MCC Gene Expression Post-Cytarabine Treatment
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure the level of expression of MCC over time following cytarabine treatment.
Details are found in Supplementary Materials.
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RESULTS
Cellular Sensitivity Phenotypes
Previously, genetic variants associated with cytarabine-induced cytotoxicity were identified in 85 CEU, 89 YRI, 83 ASW from the International HapMap lymphoblastoid cell line collection 17, 18 . In the present study, we extended these studies to increase power to detect associations and to identify cross-population SNPs. Prior to performing a metaanalysis, we evaluated an additional 89 CEU (174 total), 87 YRI (176 total), and 90 ASN (consisting of 45 JPT and 45 CHB) for cellular sensitivity to cytarabine using a shortterm growth inhibition assay. We determined the percent survival at five different concentrations for each cell line, from which AUC was calculated. 
Meta-analysis across population panels identifies SNPs associated with cytarabineinduced cytotoxicity
Using quantitative trait disequilibrium total association (QTDT), genome-wide association studies were performed in each panel of LCLs to identify SNP associations with cellular sensitivity to cytarabine. To increase the density of interrogated SNPs, ungenotyped markers in Phase III of the CEU, YRI, and ASW samples were imputed using BEAGLE. To increase statistical power, we conducted a meta-analysis on the results of the individual GWAS of each of the six panels. The meta-analysis combined the results of individual GWA studies from each panel to identify SNPs associated with cytarabine AUC across populations, accounting for sample size and direction of effect.
Approximately 60% of the most highly ranked SNPs (p < 10 -4 , n=370) had consistent allelic direction of effect in all 6 panels, as perhaps expected, since such SNPs would rise to the top of the meta-analysis results. Figure 2A illustrates a Manhattan plot summarizing the results of the meta-analysis. Table 1 lists the top 37 SNPs (p < 10 -5 ), their location, p-value and the directionality in each panel evaluated (ASN, CEU1/2, CEU3, ASW, YRI1/2, YRI3). While most of these SNPs were common (MAF > 5%) in all the panels, several SNPs were specific to a population class (e.g., monomorphic in the other populations) and therefore were not interrogated in as many individuals (Table 1, column heading: weight).
To ascertain the significance of SNPs within known candidate genes in the cytarabine pathway (CDA, NT5C2, NT5C3, SLC29A1, and DCK) 24 , we retrieved the meta-analysis p-value for each of the SNPs located within the pathway and polymorphic at MAF>5% in any of the populations examined here (Supplementary Table 1 ). Several of the SNPs in 3 genes (CDA, NT5C2, and SLC29A1) showed nominal significance in our LCL model (p<0.05).
Within the context of an unbiased genome-wide approach, we were also interested in identifying novel susceptibility loci outside the known cytarabine pathway. While no SNP reached genome-wide significance (Bonferroni) from the meta-analysis, we found that restricting the meta-analysis to SNPs that are expression quantitative trait loci (eQTLs, p < 5x10 -8 with a gene expression trait in the populations 17 for which we have genome-wide gene expression data) allowed us to identify a highly significant SNP (after Bonferroni correction, n = 4,686 tests), rs4073360 (p = 6.9x10 -6 ), that is a common (MAF > 5%) variant in all HapMap populations. Furthermore, the distribution of association pvalues for the expression-associated SNPs (at a less stringent p < 10 -4 with a gene expression trait) 25, 26 shows enrichment for low cytarabine association p-values.
A genic region that contains the highest-ranked SNP associations from the metaanalysis was identified on chromosome 5. Figure 2B illustrates a plot of the meta- ) as potential eQTLs. In particular, rs7729269 is a potential eQTL (in CEU) for the ectodysplasin A2 receptor (EDA2R) gene. We found that higher gene expression of EDA2R was significantly associated with cellular resistance to cytarabine in CEU (p=0.02) and in YRI (p=0.004).
The most significant LCL cytotoxicity SNP rs7729269 showed nominally significant associations (p < 0.05) with concordant direction of effect in YRI, ASW and ASN populations ( Figure 3A) . Each additional C allele results in lower AUC in the cytotoxicity assay and therefore confers sensitivity to cytarabine. Another SNP within MCC, rs13171482, shows concordant direction in all 4 populations ( Figure 3B ).
Evaluation of cytarabine-induced apoptosis
Using the preclinical LCL model, we phenotyped 4 LCL panels (YRI1/2, ASW, CEU1/2, CHB) for caspase 3/7 activation following treatment with 40µM cytarabine.
Upon evaluation of the top 37 cytotoxicity-associated SNPs (p < 1 x 10 -5 ) for their association with cytarabine-induced caspase 3/7 activation, 14 SNPs showed nominal association with apoptosis at a p < 0.05 (Table 1 
Evaluation of relationship of GWAS findings with intrinsic growth
Previously, we demonstrated a strong association between the rate of cellular proliferation and sensitivity to cytarabine, as measured by AUC, within each population 17, 27 . Nevertheless, we found no association (p>0.05) between any of the top 37 SNPs and intrinsic growth rate 28 . Thus, it is unlikely that the observed associations of the 37
SNPs with cytarabine-induced cytotoxicity were mediated by the rate of basal proliferation. Furthermore, the expression of the MCC gene was not correlated with intrinsic growth rate (p = 0.11).
Validation of SNPs from LCL model in clinical samples
To determine the degree to which our cell-based approach identified patients responsive to cytarabine, we evaluated SNPs (n=37) identified in LCLs at p < 1 x 10 (Table 1, Supplementary Table 2 ). These 10 SNPs also showed the same directionality for cellular sensitivity to drug as measured by LCL-cytotoxicity and LCL-apoptosis and for chemo-sensitivity of leukemic blasts from AML patients, as illustrated for rs7729269 and rs13171482 (in Figure 3C and 3D, Figure 4C ).
There were 5 SNPs (rs12036333, rs9883101, rs6550826, rs1533140, rs17202778) associated with TRM. Rare alleles were associated with greater sensitivity to cytarabineinduced cytotoxicity and with greater probability of TRM. Most TRM's were due to infection secondary to chemotherapeutic immune suppression, one was due to venoocclusive disease and another due to intracranial hemorrhage. The SNP rs12036333 was associated with LCL-cytotoxicity (p = 1.31 x 10 -6 ) with AA genotype associated with greater in vitro cytarabine sensitivity and in AML patients, AA genotype was associated with inferior overall survival (p = 0.015) as well as greater treatment-related mortality (p = 0.0037) compared to those with GA/GG genotype ( Figure 5 ).
Of the 33 SNPs tested that had an association with cytarabine-induced cytotoxicity in LCLs (p < 1 x 10 -5 ), 18 were associated (p<0.05) with cytarabine IC 50 in leukemia cells, day 22 MRD, RFS, OS, or TRM (Supplemental Table 2 ). The number of such "clinically validated SNPs" was statistically significant (p=0.016; Figure 6 ) from a permutation analysis (see Methods).
For
Effect of Cytarabine treatment on MCC gene expression
There was no significant relationship between baseline MCC gene expression and sensitivity to cytarabine as measured by cytotoxicity or apoptosis (data not shown). We surmised that a potential mechanism for sensitivity to cytarabine by SNPs within MCC Figure 2) . This induction was statistically significant at all time points tested (p=0.03 at 6 hr, 7.1x10 -10 at 18 hr, 7.1x10 -11 at 24 hr). Interestingly, the cell line (12044) with 26.6 fold induction was among the most sensitive and the cell line (12812) with 1.3 fold induction was among the most resistant to cytarabine. However, the relationship between fold change and cytarabine sensitivity failed to achieve significance in these 10 cell lines, perhaps due to small size. We also measured NFKB1expression at the same time points and saw a modest expression decrease at 24 hours (p=0.059) (data not shown).
Using limma 29 as implemented in the Bioconductor project, we re-analyzed two gene expression profiling datasets, one from a study of cytarabine-treated human diffuse large cell lymphoma cell lines versus untreated cells 30 and another from a recently deposited data into Gene Expression Omnibus involving primary AML cells treated with cytarabine (http://www.ncbi.nlm.nih.gov/bioproject/PRJNA174047) 31 . In the former, we found that MCC expression was significantly induced (p=0.029) by cytarabine treatment In addition, an intergenic SNP (rs2897047) near IRX2 and associated with cellular sensitivity to cytarabine in LCLs was associated with day 22 minimal residual disease, and relapse-free survival in AML patients. The rare alleles of 5 SNPs were associated with cytarabine-induced cytotoxicity and greater probability of treatment-related mortality. Identifying patients upfront who are highly sensitive to cytarabine may have clinical utility and improve outcomes. In total, 18 SNPs were found to be associated with a clinical outcome in AML patients, which is significantly more than expected by chance.
Previously, we demonstrated that the cumulative incidence of relapse was significantly higher among those with high levels of MRD compared to patients with low levels of MRD (P<0.0001) 2 . In this study we have identified that carriers of the TT allele of rs2897047 (near IRX2) have greater incidence of relapse and more disease burden at day 22 as determined by MRD positivity consistent with our findings in LCLs that cells with TT genotype were more resistant to cytarabine. The SNP, rs2897047, is in linkage disequilibrium with rs6872448 (r 2 = 0.87 in CEU) which is in a DNase hypersensitive site and likely to be a regulatory SNP for IRX2 based on ENCODE data in GM12891 and HeLaS3 cells 32 . Notably, three genes highly predictive of outcome in a recent Children's Oncology Group study 33 included IRX2. IRX2 expression was correlated with worse outcome in acute lymphoblastic leukemia (ALL) patients 33 .
Furthermore, of the 5 SNPs associated with cytarabine-induced cytotoxicity in and has nominal association with cytarabine-induced cytotoxicity in LCLs (p=0.002) and concordant direction of effect in all population panels examined here. The impact of this locus on response to cytarabine thus merits further investigation.
Our data related to the MCC SNPs demonstrate that: 1) Genetic variants within MCC are associated with cytarabine-induced cytotoxicity and apoptosis in LCLs; 2)
MCC variants are also associated with in vitro cytarabine sensitivity of leukemic blasts from AML patients. 3) Several SNPs within MCC (rs7729269, rs6594713, rs13181534, rs6870401, rs6887482, rs10061462, rs6594714, rs13174075) are potential eQTLs for EDA2R, a gene shown to be a direct p53 target 36 and involved in p53-mediated apoptosis 37 . EDA2R (also known as XEDAR) is a member of the TNFR superfamily that interacts with TRAFs (TNFR-associated factors) and activates the nuclear factor-κB (NF-κB) signaling, and consequently promotes cell proliferation. 4) Upon treatment of LCLs with cytarabine, there is an increase in MCC that is variable within the CEU and YRI cell lines.
Because of the clinical importance of this drug, there have been numerous studies to uncover the biological mechanisms of resistance. Evidence suggests that cytarabine activates NF-κB, a nuclear transcription factor, in myeloid cells 38 . Activation of NFκB may be accompanied by the acquisition of cytarabine resistance; the activation is
For personal use only. on November 1, 2017. by guest www.bloodjournal.org From assumed to induce transcription of genes that function in a feedback and block apoptosis 39 . Constitutive activation of NFκB is found in human leukemia stem cells but not in normal hematopoietic stem cells 40 . Interestingly, the tumor suppressor gene MCC has been shown to be a transcriptional regulator of NFκB pathway in colorectal cells 41 Recent studies from a number of groups using pre-clinical cell-based models have taken top GWAS findings identified in LCLs and validated them in prospective clinical trials 23, [45] [46] [47] . The current study further demonstrates the utility of the model system and provides an overall measure of the significance of the findings from its use in predicting response in AML patients treated with cytarabine. 
